Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs

Maria-Magdalena Georgescu1*, Mohammad Zahidul Islam2, Yan Li2, James Traylor2 and Anil Nanda3

Abstract

Prognostic molecular subgrouping of glioblastoma is an ongoing effort and the current classification includes IDH-wild-type and IDH-mutant entities, the latter showing significantly better prognosis. We performed a comparative integrated analysis of the FGFR glioblastoma subgroup consisting of 5 cases from a prospective 101-patient-cohort. FGFR alterations included FGFR2-TACC2 and FGFR2 amplifications arising in a multifocal IDH-mutant glioblastoma with unexpected 2.5-month patient survival, novel FGFR3 carboxy-terminal duplication and FGFR3-TLN1 fusion, and two previously described FGFR3-TACC3 fusions. The FGFR2 tumors showed additional mutations in SERPINE1/PAI-1 and MMP16, as part of extensive extracellular matrix remodeling programs. Whole transcriptomic analysis revealed common proliferation but distinct morphogenetic gene expression programs that correlated with tumor histology. The kinase program revealed EPHA3, LTK and ALK receptor tyrosine kinase overexpression in individual FGFR tumors. Paradoxically, all FGFR-fused glioblastomas shared strong PI3K and MAPK pathway suppression effected by SPRY, DUSP and AKAP12 inhibitors, whereas the FGFR2-TACC2 tumor elicited also EGFR suppression by ERRFI1 upregulation. This integrated analysis outlined the proliferation and morphogenetic expression programs in FGFR glioblastoma, and identified four novel, clinically targetable FGFR2 and FGFR3 alterations that confer aggressive phenotype and trigger canonical pathway feedback inhibition, with important therapeutic implications.

Keywords: FGFR2 amplification, FGFR2-TACC2, FGFR3-TACC3, FGFR3-TLN1, PAI-1, MMP, Leptomeningeal gliomatosis, Transcriptomics, Proteomics

Introduction

Glioblastoma is the most frequent malignant primary brain neoplasm in adults, with an incidence of 3–4 cases per 100,000 population, and 41% survival at 1 year [1]. Approximately 10% of the tumors harbor pathogenic mutations in IDH1/2 genes, which confer a significantly better prognosis, with a median survival of 2.5 years [2]. Many of IDH-mutant glioblastomas result from progression over 4–10 years of lower grade IDH-mutant astrocytomas, hence their name of secondary glioblastoma. IDH-wild-type and IDH-mutant glioblastoma subgroups are recognized as separate molecular entities in the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) [3]. The genetic hallmark of IDH-mutant astrocytoma, in general, is the presence of IDH1/2, TP53 and ATRX mutations, whereas IDH-wild-type glioblastomas show TERT promoter mutations, CDKN2A/B homozygous loss, TP53 and PTEN mutations, as most frequent common alterations [3]. Additional loss of chromosome arm
10q is seen in over 75% of IDH-wild-type glioblastoma and usually spans the PTEN locus at 10q23.31, and in 60% of IDH-mutant glioblastoma cases, the most commonly deleted region being 10q25-qter, encompassing the FGFR2 and DMBT1 loci [4].

The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases (RTKs) comprises four members that share a common structure and activate the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) and phosphatidylinositol 3′-OH kinase (PI3K)/AKT pathways by constitutively docking FGFR substrate 2 (FRS2) to the juxtamembrane receptor region. They also activate STATs and phosphorylate (PL) C-γ by docking them to phosphorylated tyrosine residues, the latter within the carboxyl (C)-terminal tail of the receptor [5]. FGFR driver mutations, amplifications and fusions, as well as FRS2 amplification, are seen in a variety of hematologic and solid cancers [5, 6]. In primary brain cancers, FGFR1 gain-of-function mutations, kinase domain duplications and fusions, mainly with TACC1, FGFR2 fusions with CTNNA3 or KIAA1598/SHTN1, and FGFR3-TACC3 fusions were reported [7–10]. Of these, the FGFR3-TACC3 fusions are the FGFR alterations most commonly occurring in IDH-wild-type glioblastoma [11].

We characterized in this study a spectrum of FGFR alterations from a cohort of 101 WHO grade IV diffuse gliomas, including novel FGFR2 and FGFR3 fusions, the former taking place in IDH-mutant glioblastoma, a neoplasm previously not known to harbor oncogenic FGFR alterations [9]. By using an integrated proteogenomic approach coupled to temporospatial tumor sampling, we defined both common and unique signaling patterns for the FGFR tumors. In particular, FGFR2 or FGFR3 fusions inducing RTK multimerization activated potent inhibitory feedback loops suppressing the hyperactivation of the canonical MAPK and PI3K pathways, with potential implications for FGFR-targeted therapy.

Material and methods

Tumor specimens, autopsy, histology and tumor burden quantification

Surgical resection or biopsy specimens were obtained from patients with glioblastoma, as previously described [12], in accordance to hospital regulations. The autopsy was performed as previously described [13], following the patient’s husband consent for diagnosis and research. A recently described standardized autopsy sampling protocol was applied [14]. FFPE sections from autopsy and surgical specimens were stained with hematoxylin–eosin (H&E). Images were acquired with Nikon Eclipse Ci microscope equipped with Nikon Digital Sight DS-Fi2 camera (Nikon Instruments Inc., Melville, NY), as previously described [15]. The histologic tumor burden was quantified on a 0-to-4 scale, as described [14].

Numerical data were represented graphically by using GraphPad Prism (Version 8.3.0, GraphPad Software, La Jolla, CA).

Immunohistochemistry (IHC)

IHC was performed on selected sections, as described [12, 15]. The following primary antibodies were used: histone H3-K27M (Millipore/Sigma, Burlington, MA), IDH1-R132H (DIA-H09, Dianova, Hamburg, Germany), p53 (DO-7), vimentin (V9), Ki-67 (30-9) (Roche/Ventana Medical Systems Inc., Tucson, AZ), Olig-2 (387M-15), GFAP (EP672Y) (Ventana/ Cell Marque, Rocklin, CA).

Transmission electron microscopy

Freshly collected autopsy tumor samples were processed for electron microscopy, as previously described [15, 16]. Digital images were obtained by using AMT Image System (Advanced Microscopy Techniques, Danvers, MA).

Next generation sequencing (NGS) and copy number variation (CNV)

Nucleic acids were extracted from fresh frozen or FFPE samples, as previously described [12]. FFPE section microdissection was performed for the F48 pituitary section in order to separate normal tissue from neoplastic invasion. NGS was performed in two distinct laboratories for F48 normal and tumor samples. Moreover, F48 autopsy LM54 and DL56 were sequenced from both frozen and FFPE samples, with similar results. The NGS libraries used were: Tempus xT 596-gene or xE whole exome panels [16, 17] for all samples and the customized 295-gene panel [12] for all F48 samples. Variant analysis and interpretation were performed as previously described [12, 16, 17]. CNV analysis was performed as previously described [14]. Gene amplification was called for CN ≥ 8, and loss of heterozygosity (LOH) for alterations with loss of one allele. Tumor mutation burden (TMB) is expressed as single-nucleotide protein-altering mutations per megabase DNA.

Transcriptomics and statistical analysis

Whole transcriptome RNA sequencing was performed from FFPE-extracted RNA using an exome-capture-based RNA sequencing protocol, as described [18] (Tempsus Labs) for all glioblastoma samples with more than 30% tumor on FFPE sections. Briefly, reads were aligned to GRCh38 using STAR (v2.4.0.1), and expression quantitation per gene was computed using FeatureCounts (v1.4.6). Raw read counts were normalized to correct for G+C content and gene length using full-quantile normalization and adjusted for sequencing depth via the
| Sex/age | Race/smoker | Cancer history | Location | Size (cm) | Res | RT/TMZ/Avastin | Survival (months) | Histology | MGMT | TMB | FGFR alteration |
|---------|-------------|----------------|-----------|-----------|-----|----------------|-------------------|------------|------|-----|-----------------|
| F48     | W No        | No             | R Temp    | 4 × 2     | 2×  | None           | 2.5               | HG-Embryonal | neg  | 2.1 | FGFR2↑          |
| M60     | W No        | No             | L Frontal | 4 × 3.4   | 2×  | RT/TMZ/A       | 20                | HG-LM Rhabdoid |      | 0.8 | FGFR3-TACC3,FRS2↑ |
| F62     | W No        | BrCa<sup>a</sup> | R Par     | 3.5 × 3   | 2×  | RT/TMZ         | 7.3               | RMF FGFR3    | neg  | 5.8 | FGFR3 Ctdup, FRS2↑ |
| F72     | W No        | BrCa<sup>b</sup>| R Temp    | 6.8 × 4.5 | 1×  | RT/TMZ/A       | 23                | RMF FGFR3    | low  | 5.8 | FGFR3-TACC3     |
| F75     | W No        | No             | R Temp    | 7.4 × 3.8 |     | LITT           | None<sup>c</sup>  | RMF FGFR3    | high | 3.2 | FGFR3-TLN1      |

<sup>a</sup> Surgically resected breast cancer

<sup>b</sup> History of Hashimoto thyroiditis and arteriosclerosis (myocardial infarction and stroke)

<sup>c</sup> TMZ not tolerated

*F* female, *M* male, *W* white, *BrCa* breast cancer, *R* right, *L* left, *Temp* temporal, *Par* parietal, *Res* surgical resection, *LITT* laser interstitial thermal therapy, *RT* radiotherapy, *TMZ* temozolomide, *HG* high grade, *LM* leptomeningeal, *LG* low grade, *DI* diffusely infiltrating astrocytoma, *RMF* recurrent morphologic features of FGFR3 glioblastoma, *MGMT* methylguanyl methyl transferase promoter methylation, *TMB* tumor mutation burden, † amplification

---

**Table 1** FGFR glioblastoma patients: clinical-histologic-molecular correlations
size factor method. RNA fusions were detected by quantifying gene-level expression and chimeric transcripts through non-canonical exon-exon junctions mapped using split or discordant read pairs. The expression analysis parameters included threshold setting for total RNA counts $\geq 500$ in at least one tumor sample, exclusion of amplified loci, pseudogenes and Y-chromosome genes, and $\geq$ fivefold expression threshold setting for FGFR tumors relative to DI$_{50}$ values. Gene classification in 12 non-overlapping functional categories was performed by individual curation. Gene category overexpression median ranking was calculated by using non-parametric, two-tailed Wilcoxon matched-pairs signed rank test. The graphic, statistic and gene classification software included Microsoft Excel (Microsoft Corp., Redmond, WA), GraphPad Prism, and GeneVenn (http://www.bioinformaticso.org/gvenn).

Proteomic analysis
Fresh frozen tissue lysis and Western blotting (WB) were performed as previously described [14]. The primary antibodies are provided in Additional file 1: Table S1, and many were previously tested in autopsy tissue [14]. WBs for each antibody were repeated at least twice, with similar results. The densitometric analysis was performed by scanning the X-ray films with optimal exposures on a ChemiDoc™ Touch imager (Bio-Rad, Hercules, CA). The bands were quantified by using Image Lab 6.0 software (Bio-Rad). Individual protein values were normalized to the corresponding actin or IDH1-R132H values, except for phosphoprotein values that were normalized to the corresponding unphosphorylated protein values. Minus values were manually adjusted as zero. Results were expressed as percent of the highest normalized values.

Three-dimensional (3D) modeling
The 3D structure of human wild-type PAI-1 engineered to have a long half-life allowing an active conformation [19] (Protein Data Base accession number: 3r4I) was used to model wild-type R210 and mutant H210 residues. Surface models were generated by using PyMol Molecular Graphics System (Version 2.3.0, Schrodinger, LLC), as previously described [13, 20].

Results
Clinical overview of glioblastoma FGFR subgroup shows aggressive leptomeningeal (LM) disease linked to FGFR2 alterations
The genomic analysis of a prospective 101 adult patient glioblastoma cohort revealed FGFR alterations in five de novo glioblastomas (Table 1). Four of these were IDH-wild-type glioblastomas with FGFR3 alterations (FGFR3 glioblastoma), occurred in older patients (median age 67 years) and resulted in a 13.6-month median survival. Except for the oldest patient with co-morbidities that had a large, unresectable tumor treated by laser interstitial thermal therapy, the three other patients were amenable to gross total resection followed by radiochemotherapy. Notably, two of the three female patients had prior history of surgically-resected breast cancer (Table 1). Histologically, the FGFR3 glioblastomas showed intense GFAP reactivity and various degrees of “FGFR3-TACC3 glioma recurrent morphological features” [21], in addition to high-grade (HG) features, such as brisk mitotic activity, necrosis and microvascular proliferation (Additional file 1: Fig. S1).

The tumor from the youngest FGFR patient, F48, had FGFR2 alterations and a very aggressive course, resulting in rapid general status decline that precluded post-resection attempts to radio- and chemotherapy (Table 1, Fig. 1a). F48 was admitted following seizure on the left side of her body with loss of consciousness at work. She also complained of tingling in her 3rd, 4th and 5th digits for 2–3 weeks prior admission, and of occasional headaches and vision blurring for years. Brain magnetic resonance imaging (MRI) showed a right temporal, $4 \times 2$ cm, rim-enhancing mass, hyperintense on T2-weighted (W) images and hypointense on T2W-FLAIR (Fig. 1b). T2W-FLAIR showed also peri-insular and posterosuperior temporoparietal white matter infiltration (Fig. 1b), and T1W post-contrast images showed contrast enhancement lining the Sylvian fissure, suggestive of LM infiltration (Fig. 1b; Additional file 1: Fig. S2A). Gross total resection (Res$_1$) and histopathological examination of the rim-enhancing mass revealed a gelatinous neoplasm with embryonal/HG neuroendocrine morphology, abundant myxoid extracellular matrix (ECM), necrosis, microvascular proliferation and a very high mitotic index, with up to 33 mitotic figures per 1 high power field (Fig. 1c; Additional file 1: Fig S2B). GFAP was positive in a small subset of neoplastic cells, and IDH1-R132H and p53 were diffusely positive in neoplastic cells (Fig. 1c). MGMT gene promoter methylation was negative (Table 1). The diagnosis rendered was glioblastoma, IDH-mutant, WHO grade IV, roughly predicting a 2.5-year median survival. An MRI performed one month later was suspicious for meningitis or LM gliomatosis, for which the patient was placed on antibiotics without improvement. A second resection (Res$_2$) was performed consisting of re-resection of the initial mass, of a second lower temporal mass, and of multiple dura mater biopsies. Histopathological examination showed LM gliomatosis exhibiting rhabdoid tumor cell morphology, necrosis, and extensive loss of GFAP expression (Additional file 1: Fig. S2B). Following the second surgery, F48 was placed in hospice, and expired 2 weeks later, with a post-surgery survival of
Fig. 1 Three radiologically and histologically different neoplasms in F48 IDH-mutant glioblastoma with FGFR2 alterations. **a** Timeline of disease progression. **b** Initial axial MRI shows a rim-enhancing, T2W hyperintense and T2W-FLAIR hypointense mass (blue arrow), Sylvian fissure enhancement (red arrow), and extensive white matter infiltration (green arrow), each corresponding to a different tumor. **c** H&E and IHC with indicated antibodies of the resected rim-enhancing mass (Res1). Note HG neuroendocrine/embryonal morphology with hyperchromatic nuclei and frequent mitoses (arrow). IHC with Cam5.2, TTF-1, HMB-45, p40, p63, CD45, estrogen receptor and mammaglobin to exclude a metastatic neoplasm showed negative results (not shown). **d** Autopsy showing the entire brain base covered in a thick, nodular, hyperemic or hemorrhagic LM infiltrate. **e** Gross and microscopic appearance of the HG LM infiltrate. Sections S3 and S4 show the resection site (blue arrows) and the Sylvian fissure LM neoplasm (red arrow). H&E and IHC with indicated antibodies of the Sylvian fissure LM tumor (LM_{S4}). **f** H&E and IDH-R132H reactivity of the LG DI neoplasm from S6 white matter (DIS6). **g** Close-up H&E of the HG LM component showing rhabdoid cells embedded in myxoid ECM. **h** Ultrastructural evaluation showing true rhabdoid cells with perinuclear whorls of intermediate filaments, and numerous mitotic figures. IHC for vimentin shows strong positivity in the whorls.
10 weeks. An autopsy was performed within 3 h postmortem. The recorded brain weight was 1215 g, slightly lower than the normal range for age and gender, most likely due to prior resections. The leptomeninges overlaying the base of the brain contained a thick, granular or frankly nodular infiltrate with focal areas of hyperemia, hemorrhage or necrosis, filling the interhemispheric space and encasing all the structures at the base (Fig. 1d). At sectioning, two masses were apparent in the right temporal lobe: a 6 × 4 cm hematoma containing white nodular infiltrate and corresponding to the previous resection sites, and an adjacent 3-cm-diameter necrotic mass in the Sylvian fissure, involving the anterior insula (Fig. 1e; Additional file 1: Fig. S3). Effacement of the grey-white matter junction and induration of the subjacent white matter extended posteriorly in the Heschl's transverse and upper temporal gyri (Additional file 1: Fig. S3, green arrow). Histopathological examination revealed massive infiltration of the leptomeninges by a HG mucinous neoplasm with extensive geographic necrosis and viable cells arranged around vessels (Fig. 1e). IHC showed diffuse positivity for p53, Olig2 and IDH1-R132H, but GFAP was retained only in a small perivascular subset, similarly to the Res2 specimen. In contrast, the diffusely infiltrating (DI) astrocytic neoplasm corresponding to the induc-

tantly, DIS6 also contained the IDH1-R132H mutation (Fig. 2a–c; Additional file 1: Fig. S4). Impor-
tantly, DiM also contained the FGFR2-TACC2 fusion with LOH. The fusion RTK contained all FGFR2 amino (N)-terminal domains, including the entire tyrosine kinase (TK) domain, and swapped the FGFR2 54-residue C-terminus for the intact 239-residue TACC domain (Fig. 2c; Additional file 1: Table S3).

The FGFR3 glioblastoma cases exhibited the most common mutations found in IDH-wild-type glioblastoma [3], with CDKN2A homozygous loss in all cases, followed by PTEN mutations with LOH and CDKN2B homozygous loss, in three cases, and TERT c.124C>T promoter mutation in two cases (Fig. 2a, Additional file 1: Table S2). FRS2 and neighboring oncogene YEATS4 amplification were present in two cases. Putative germline pathogenic mutations, as assessed by their homozygous variant allele frequency and from previous reports, were present in the female patients with breast cancer history, such as MUTYH p.G396D (ClinVar, 33 submitters) and RB1 p.R451H (ClinVar, 2 submitters) in F62 and F72, respectively. M60 presented additional pathogenic alterations of the DNA damage response (DDR) pathway, and F75 showed pathogenic mutations in multiple tumor suppressor genes, such as DEPDC5 p.W905*, an mTOR inhibitor [23], and several nuclear DNA remodelers. The FGFR3 alterations consisted of two distinct, previously reported FGFR3-TACC3 fusions [10], a novel FGFR3 C-tail insertion with duplication (FGFR3 Ctdup), and a novel FGFR3-TLN1 fusion (Fig. 2a, c; Additional file 1: Table S3). The FGFR3 Ctdup contained an extra 76-resi-
due insertion that added a novel Proline-rich region with a putative PXXXPX PAK-binding motif, as well as non-
canonical SH3-interacting motifs [24, 25], and duplicated the first half of the C-tail, including the PLCγ interaction.

Novel FGFR alterations in glioblastoma

NGS was performed on six F48 samples, including normal tissue, and on the four FGFR3 glioblastoma surgical specimens. F48 showed the common somatic mutation signature of IDH-mutant astrocytomas comprising the IDH/TP53/ATRX triad [3]: IDH1 p.R132H, TP53 p.I232S with LOH, and ATRX p.H2252R, which represents a novel ATRX mutation (Fig. 2a, b; Additional file 1: Table S2). Interestingly, additional common somatic mutations occurred in the SERPINE1 p.R210H, a hotspot in colorectal cancer [22], and MMP16 p.Y290H ECM remodelers. Pathogenic somatic mutations in PIK3CA p.E545K and BRCA2 p.C2765F were present only in the F48 resections. F48 also showed a germline BRCA2 T2337I variant of unknown significance (VUS) (ClinVar, multiple submitters). FGFR2 or FGFR2-TACC2 fusion amplifications, resulting in massive mRNA overexpression, were present in all F48 HG specimens, and correlated with the embryonal or rhabdoid morphology, respectively (Fig. 2a–c; Additional file 1: Fig. S4). Importantly, DiM also contained the FGFR2-TACC2 fusion with LOH. The fusion RTK contained all FGFR2 amino (N)-terminal domains, including the entire tyrosine kinase (TK) domain, and swapped the FGFR2 54-residue C-terminus for the intact 239-residue TACC domain (Fig. 2c; Additional file 1: Table S3).

The FGFR3 glioblastoma cases exhibited the most common mutations found in IDH-wild-type glioblastoma [3], with CDKN2A homozygous loss in all cases, followed by PTEN mutations with LOH and CDKN2B homozygous loss, in three cases, and TERT c.124C>T promoter mutation in two cases (Fig. 2a, Additional file 1: Table S2). FRS2 and neighboring oncogene YEATS4 amplification were present in two cases. Putative germline pathogenic mutations, as assessed by their homozygous variant allele frequency and from previous reports, were present in the female patients with breast cancer history, such as MUTYH p.G396D (ClinVar, 33 submitters) and RB1 p.R451H (ClinVar, 2 submitters) in F62 and F72, respectively. M60 presented additional pathogenic alterations of the DNA damage response (DDR) pathway, and F75 showed pathogenic mutations in multiple tumor suppressor genes, such as DEPDC5 p.W905*, an mTOR inhibitor [23], and several nuclear DNA remodelers. The FGFR3 alterations consisted of two distinct, previously reported FGFR3-TACC3 fusions [10], a novel FGFR3 C-tail insertion with duplication (FGFR3 Ctdup), and a novel FGFR3-TLN1 fusion (Fig. 2a, c; Additional file 1: Table S3). The FGFR3 Ctdup contained an extra 76-residue insertion that added a novel Proline-rich region with a putative PXXXPX PAK-binding motif, as well as non-canonical SH3-interacting motifs [24, 25], and duplicated the first half of the C-tail, including the PLCγ interaction.
The FGFR3-TLN1 fusion joining the FGFR3 TK domain to talin C-terminal half resulted from chromosomal translocation. Talin is the cytoskeletal protein that couples F-actin to integrins at the focal adhesions, and the moiety involved in the FGFR3-TLN1 fusion included the F-actin-binding region and the C-terminal dimerization domain [26]. This talin moiety is predicted to constitutively activate the fused FGFR3 via dimerization, similarly to other FGFR fusions [27], and possibly mislocalize it via interaction with the F-actin-binding region.
actin cytoskeleton rather than with microtubules as the TACC domain [10, 28].

The CNV analysis showed only two common CN alterations for all F48 samples: chromosome 4q and 11p heterozygous losses (Fig. 2d; Additional file 1: Table S4). The three F48 HG samples contained one common 17q21.33-qter gain and several CN losses: 3p22.2-p21.1, 5q, 10q23.31-qter except for the WDR11-FGFR2-TACC2 locus, and 21, which partially overlapped with the 21q22.11-qter loss from D1S6. Unique CNVs were present in all the samples but they were numerous for the LG D1S60, suggesting divergent evolution. All FGFR3 glioblastoma cases showed chromosome 10 deletion, and the overlap with the F48 10q23.31-qter deletion represented the only common CNV alteration between the FGFR3 and FGFR2 glioblastomas. Complete or partial chromosome 7 gain and chromosome 22 loss, which are other common chromosomal aberrations in IDH-wild-type glioblastoma [3], were present in three and two cases, respectively, whereas F72 had neither, showing unexpected chromosome 7 neutral LOH. Focal CNVs were better documented in the surgical samples from F48 and F75 for which whole exome NGS was performed (Additional file 1: Table S4). For the genes with CN gain ≥ 5, the RNA expression was analyzed and showed that only a minority resulted in overexpression (Fig. 2e). Only MYCN, ANKRD16, involved in translation fidelity [29], BMI1, encoding a major component of the Polycomb repressive complex 1 involved in transcriptional repression and DDR [30], and FGFR2 were highly overexpressed in all F48 HG tumors. M60 tumor exhibited two chromosome 12 loci resulting in high gene overexpression, including of MDM2, YEATS4 and FRS2 (Additional file 1: Table S4).

Gene expression programs in FGFR glioblastoma correlate with morphology

Comparative gene expression analysis was performed for samples with available whole transcriptomics data. The unsupervised analysis of the FGFR glioblastoma gene expression uncovered a total of 686 genes with ≥ five-fold overexpression compared to D1S6 values, further classified in 12 functional categories (Fig. 3a). The large majority of the overexpressed genes, composed mainly of cell cycle genes, was shared between FGFR3 and FGFR2 tumors (Fig. 3b). Pairwise, Res1/F2↑–LM3S/F2T2↑, and F2T2↑–FGFR3 showed significant overlap of cell cycle and ECM/growth factor genes, respectively. F2↑ showed specific predominance of G protein-coupled receptors (GPCRs). Within the FGFR3 subgroup, gene overexpression unexpectedly showed more overlap between M60 and F75 tumors that harbored FGFR3 fusions with different partners than between M60 and F72 (Fig. 3c). The discrepancy was caused by a set of chromatin and cell cycle genes that were not significantly upregulated in the F72 tumor, suggesting less aggressive proliferation. The F72 and F75 tumors shared genes mediating inflammation and angiogenesis, whereas ALK and ALPK2 kinases were specifically expressed in each tumor, respectively.

To understand the biology of the tumors, each functional gene category was compared between the morphologically different F2↑, F2T2↑ and FGFR3 tumors. The ranking of overexpression values in tumor proliferation categories, such as cell cycle, DDR and chromatin, showed F2↑, followed by F2T2↑, as the most proliferative tumors (Additional file 1: Fig. S6). In-depth analysis of cell cycle genes showed high upregulation of genes governing S and M phases, as well as of cell cycle checkpoint genes in the FGFR2 subgroup (Fig. 3d). The examination of cyclin, CDK, and CDK inhibitor expression levels showed distinct upregulation of G1-phase CDK4 in FGFR2 tumors, and cyclin D2 and CDK6 in FGFR3 tumors. CDKN2A and CDKN2B expression correlated perfectly with their homozygous CN loss in the FGFR3 tumors (see Fig. 2a), and showed also decrease in the FGFR2 tumors, in the absence of CNV. Among druggable cell cycle and chromatin genes, TOP2A, TYMS, TERT, EZH2, ODC and HDAC2 showed high overexpression levels in FGFR2 tumors (Fig. 3e). Within the FGFR3 subgroup, M60 and F75 showed lower but comparable cell-cycle-related overexpression values to FGFR2 tumors, while F72 had consistently low values, including for TERT that harbored the c.124C>T promoter mutation. Many of the DDR genes from the BRCA1/2 complex that is recruited to RAD51 DNA-damage foci [31] showed massive overexpression in the FGFR2 tumors (Fig. 3f).

Overexpression ranking in functional categories reflecting tissue specification, environment and architecture, placed generally F2T2↑ and FGFR3 tumors close together, with more developed programs than F2↑ (Additional file 1: Fig. S6). The transcription factor category was rather heterogeneous, consisting of common or more specific factors (Fig. 3g). Of these, the INSM1-RCOR2 repressor complex specifying neuroendocrine development [32], was overexpressed in the F2↑ and F75 tumors. Interestingly, another transcription repressor DACH1, known to mediate a negative FGF signaling feedback loop through FGF2 repression [33, 34], showed ≥ 15-fold specific overexpression in the F2↑ tumor.

The closely related ECM and growth factors expression programs showed the most complex activity in the F2T2↑ tumor, followed by FGFR3 tumors (Additional file 1: Fig. S7). Although many of the signaling pathways shown were significantly upregulated in F2T2↑, most were shared with the other tumors, noteworthy being the ALK and insulin receptor RTK pathways. For the cell
Fig. 3  Gene expression programs in FGFR glioblastoma. a Vertical slice chart representing the ensemble of ≥ fivefold overexpressed genes from FGFR tumors classified in functional categories. The number of genes in each functional category is shown. b Venn diagram depicting the sharing of the same gene ensemble as in a between FGFR2 tumors (Res/F2↑ and LM/F2T2↑) and the FGFR3 subgroup. Horizontal-slice charts of functional gene categories are shown for each of the 7 Venn diagram subsets. c Venn diagram of the ≥ fivefold overexpressed genes for the three FGFR3 cases with available RNA expression data: M60 and F72, sharing the FGFR3-TACC3 (F3T3) fusion, and F75 showing FGFR3-TLN1 (F3TLN1) fusion. The overexpressed genes from the two M60 amplified loci on chromosome 12 were not included in the expression analysis except for PTHLH, which encodes the hormone responsible for the hypercalcemia of malignancy. The functional gene categories or examples of genes associated with different Venn diagram subsets are boxed, with kinases, in magenta, and transcription factors, in blue. d Color-coded floating-bar graph for G1-, S- and M-phase and checkpoint (Cp) cell cycle genes. Fold-overexpression heatmaps are shown for cyclins/CDKs, and for CDK inhibitors. The corresponding CDKs inhibited by each inhibitor are listed. e Fold-overexpression heatmap of selected proliferation enzymatic therapeutic targets and MKI67. f Diagram and fold-overexpression heatmap of the BRCA1/2 DDR complex. Red and green arrows show recruitment to and repair of DNA damage, respectively; genes in blue are not overexpressed. g Venn diagram with representative examples of overexpressed transcription factors. h Mean ± SEM mRNA expression graph for intermediate filament genes. i j Fold-overexpression heatmaps for the GPCR and Kinase functional categories. RTKs are boxed. k Mean ± SEM graph showing FGFR3 and FGFI-2 mRNA fold expression levels. CNV analysis showed normal 2-copy complement for FGFR3, and loss of one copy for FGF2 for all F48 tumors. FGF1 showed loss of one copy in F2↑ and F2T2↑, and normal complement in LG DIS6 control.
adhesion/organization program, a common core of actin cytoskeleton genes was upregulated in all tumors (Additional file 1: Fig. S7). Important differences distinguished FGFR2 from FGFR3 tumors. Selective upregulation of a different subset of glycosylation and sulfation ECM remodeling enzymes was present in FGFR2 tumors, most likely explaining their mucinous background. Cytokines and their receptors, pro-angiogenic factors, and inflammatory mediators were predominantly upregulated in the FGFR3 tumors. Importantly, very high VEGFA expression values were noted in F2T2↑ and FGFR3 tumors. FNI encoding fibronectin, the ligand for integrins, and the integrin cell adhesion program were robustly increased in FGFR3 tumors, suggesting an essential difference in a major ECM adhesion signaling pathway. Two signaling pathways were predominantly upregulated in F2T2↑: Wnt, and Sonic Hedgehog (SHH) and related ciliogenesis pathway. The F2↑ tumor showed a complementary pattern of low expression for all intermediate filament genes, and high overexpression for most genes involved in cell–cell junctions. The intermediate filaments NEST, VIM and PRPH were overexpressed, whereas GFAP was underepressed in FGFR2 tumors, consistent with the IHC results (Fig. 3h).

Signaling through GPCR and kinases showed relatively specific profiles in FGFR tumors. The GPCRs showed complementary overexpression profiles for F2↑, F2T2↑ and FGFR3 tumors (Fig. 3i). In particular, F2↑ overexpressed a neuroendocrine receptor program, including TSHR, TACR1, RGR, LGR5 and GRM8. Eleven kinases other that FGFR2 showed ≥fivefold overexpression in the FGFR tumors, the commonly overexpressed being STK32B (Fig. 3j). EPHA3, LTK, an ALK homologue, and ALK were the only RTKs of the category, and showed specific overexpression in F2↑, F2T2↑, and F72, respectively. Among the FGFR family, FGFR3 expression was mildly increased in FGFR3 tumors, but 15-fold underepressed in the FGFR2 tumors, (Fig. 3k). In addition, FGFI and FGFP expression levels showed 111-fold and 2.5-fold decrease, respectively, in the FGFR2 tumors, suggesting an FGFR2-mediated negative feedback.

**Lack of canonical pathway activation in FGFR-fused glioblastoma relies on activation of inhibitory feedback loops**

To evaluate the activation of canonical growth signaling pathways, WB proteomic analysis was performed for F48 LM54 and DI56 (Fig. 4a, b; Additional file 1: Fig. S8). Consistent with the IHC and NGS results, both LG and HG F48 tumor components expressed IDH1-R132H. Epigenetic changes consisted of upregulation of histone H3 in both components, although less prominent in DI56. K27 trimethylation was detected only in LM54 and correlated with overexpression of EZH2. SMARCB1, the core component of the SWI/SNF chromatin remodeling complex that is mutated in rhabdoid neoplasms [35], was overexpressed only in LM54, suggesting that the rhabdoid morphology of the LM component is not due to SMARCB1 mutation. The p53 levels were mildly increased, due to mutant protein stabilization. The CDK inhibitors p16 INK4A/CDKN2A and p27Kip1/CDKN1B were either not expressed or showed significant downregulation compared to control, respectively, correlating with the mRNA expression results. The stem cell factor SOX2 that is required for maintenance of undifferentiated neural stem cells [36] showed high expression in LM54, but also moderate levels in DI56. The analysis of NF-κB pathway downstream of cytokine signaling showed strong or moderate upregulation of p65 RelA in LM54 and DI56, respectively, whereas p50 levels were comparable to normal white matter control. Focal adhesion kinase (FAK), a non-RTK implicated in cell migration downstream of integrin signaling [37], was strongly upregulated in both components, but more prominently in LM54, in the absence of phosphorylation or significant RNA expression increase, implicating protein stability as an important mechanism of protein expression levels. The hyaluronic acid receptor CD44 that has been shown to be upregulated in glioblastoma compared to LG astrocytoma [38] was unexpectedly overexpressed in DI56. CD44 interacts with c-SRC kinase [39], and CD44 upregulation correlated with c-SRC activation, although c-SRC total expression levels were upregulated in both components.

SMAD4, the common transducer of TGF-β and bone morphogenic protein signaling, and its transcriptional target plasminogen activator inhibitor 1 (PAI-1) encoded by SERPINE1 gene [40] showed upregulation in both components, more elevated in LM54 for PAI-1. PAI-1 R210H somatic mutation maps to a short β-strand in the Serpin domain exposed to the surface, relatively close to the reactive center loop that is the site of interaction with urokinase plasminogen activator (uPA) [41]. The missense mutation H210 induces a relatively significant surface change that may interfere with uPA binding (Fig. 4c). In addition to the mutation, PAI-1/SERPINE1, but also its enzymatic targets uPA/PLAU, tPA/PLAT, and their receptors uPAR/PLAUR, annexin A2/ANXA2 and p11/S100A10 forming the ECM remodeling fibrin cluster were overexpressed to various levels in LM54/F2T2↑, but also in the FGFR3 tumors (Fig. 4d). The membrane-type metalloproteinase MMP16 exhibiting a Y290H mutation mapping to the C-end of the peptidase domain showed similar levels in all samples, consistent with its reported expression in glioma and normal brain [42]. However, it demonstrated only the active processed form [43] in LM54 (Fig. 4a, red arrow). This active form cleaves and
activates MMP2, one of the gelatinases that have been consistently involved in cancer metastasis [44]. As the fibrin cluster, the peptidase cluster contained many differentially overexpressed MMPs, including MMP2, in the LMS4/F2T2↑ tumor but also in FGFR3 tumors (Additional file 1: Fig. S7).

FGFR2 expression was massively and exclusively upregulated in LMS4, and even high exposure failed to show expression in DIS6, consistent with the genomic and transcriptomic results. The main massively overexpressed band in LMS4 migrated approximately 20 kDa upper than the overexpressed wild-type FGFR2 from other HG glioma samples [14], most consistent with the molecular weight of FGFR2-TACC2 (Fig. 4a, blue arrow). EGFR, which is known to be upregulated in infiltrating gliomas [45], showed very low expression in LMS4, unlike other tested glioblastomas [38], and moderate overexpression in DIS6, without phosphorylation. PDGFRs exhibited complementary expression, with PDGFRα showing higher expression in LMS4, and PDGFRβ, in...
were activated in the LG but not in LM, a finding uncommon for HG gliomas that usually show both ERK and AKT pathway activation [14, 46]. The PI3K/AKT pathways inhibitors PTEN and PHLPP1-2 [46] were expressed in both components, with PTEN and PHLPP1 showing decreased levels in LM, contrasting with the lack of AKT activation.

FGFRs signal through FRS2 and GRB2 adaptors to activate the canonical ERK/MAPK and PI3K pathways but may also elicit negative feedback loops [5]. Whole transcriptomics showed that 8 of the 686 overexpressed genes are RTK signaling inhibitors (Fig. 4e). The FGFR signaling inhibitors Sprouty (SPRY) 1, 2 and 4, which inhibit the activation of both PI3K and ERK, and Dual-specificity phosphatases (DUSP) 4, 5 and 6 that directly dephosphorylate ERK1/2 showed highest levels in the LM/F2 tumor, explaining the downregulation of ERK in Fig. 4a). AKAP12, an A-kinase anchoring protein and ERK inhibitor [48] were expressed in both components, with PTEN and PHLPP1 showing decreased levels in LM, contrasting with the lack of AKT activation.

ERRFI1 expression was specifically and strongly (16-fold) upregulated in the LM/F2 tumor, explaining the downregulation of ERK in Fig. 4a). AKAP12, an A-kinase anchoring protein and ERK inhibitor [48] showed mRNA overexpression in LM/F2 and FGFR3 tumors. RALT/ERRFI1, another RTK inhibitor transcriptionally upregulated by ERK activation, is an EGFR catalytic inhibitor and degradation inducer [47]. ERRFI1 expression was specifically and strongly (16-fold) upregulated in the LM/F2 tumor, explaining the downregulation of ERK in Fig. 4a). AKAP12, an A-kinase anchoring protein and ERK inhibitor [48] showed mRNA overexpression in LM/F2 and FGFR3 tumors. Taken together, these data suggest that the lack of the canonical pathway activation observed in the LM/F2 tumor is most likely due to a potent negative feedback aligning multiple RTK/MAPK/PI3K inhibitors.

Discussion

The WHO molecular subgrouping into IDH-wild-type and IDH-mutant glioblastoma emphasizes a significantly longer survival for the IDH-mutant subgroup, due to a slower tumor growth rate, and reflected in a more insidious onset [4]. Although most IDH-mutant cases conform to this biological behavior, we describe here the first case of de novo IDH-mutant glioblastoma with FGFR2 alterations that induced fulminant progression with LM spread, resembling the most aggressive cases of IDH-wild-type glioblastoma. To better understand the role of FGFR in glioblastoma, we performed a comparative genomic, transcriptomic and proteomic analysis for the FGFR tumors from a prospective pediatric patient cohort with WHO grade IV diffuse gliomas. We found that the multifocal FGFR2 tumors exhibited relatively unique morphogenetic programs, whereas the four FGFR3 IDH-wild-type tumors showed relative histologic and signaling homogeneity. Despite apparent FGFR3 subgroup homogeneity, patient survival was significantly better for the cases with FGFR3 C-terminal duplication or FGFR3-TLN1 fusion that shared a more posterior location and chromosome 22 loss.

By performing autopsy and corroborating findings with the patient’s clinical history, we revealed that an undiagnosed pauci-symptomatic LG astrocytoma slowly progressed in F48 before the HG neoplastic populations emerged (Fig. 5a). For secondary IDH-mutant glioblastoma evolving from LG astrocytoma, Ohgaki et al. proposed the loss of 10q25-qter region as contributing to the malignant transformation [49]. In F48, a paradoxical FGFR2 locus amplification on 10q26.13 with CN loss of 10q25-qter resulted in massive FGFR2 overexpression. Although novel to brain tumors, FGFR2 amplification has been reported in gastric cancer where it imparts poor prognosis [50, 51], triple-negative breast cancer, hormone-resistant prostate cancer and in an isolated case of colorectal carcinoma [52–55]. In contrast, FGFR2-TACC2 fusion without amplification has only been reported in a case of apocrine breast cancer [56], despite the fact that FGFR2 fusions with various partners, including FGFR2-TACC3, are relatively common in intrahepatic cholangiocarcinoma [27]. Therefore, the F48 LM tumor is the first case showing amplification of the rare FGFR2-TACC2 fusion. Noteworthy, both fused and unfused amplified FGFR2 products are targetable molecular alterations, and current clinical protocols in gastric cancer and cholangiocarcinoma address with some success both forms [6, 27]. It is not clear what triggered the amplification of the FGFR2 locus, but it appeared to coincide with the 10q23.3-qter loss, as well as with a turning point where MYCN and BMI1 amplifications with overexpression, distinguished the LG and HG populations (Fig. 5a). Of these, MYCN amplification has been previously reported and shown to correlate with shorter survival in IDH-mutant glioblastoma [57, 58], and may have contributed to the aggressive course of this case, as well. Interestingly, a second turning point involved the separate evolution of the two main HG populations, in which F2 acquired higher genomic instability, especially of chromosome 10, but also pathogenic mutations in PIK3CA and BRCA2. The BRCA2 somatic mutation may have contributed to genome instability together with the germline BRCA2 VUS, malfunctioning within an unregulated BRCA1/2 complex shown here to be a DDR housekeeping mechanism in all highly-proliferating tumors.

The tumor biological behavior was assessed by a well-structured gene expression functional classification addressing proliferation and morphogenesis. The proliferation programs ranked FGFR2 and most FGFR3 tumors as highly proliferative, and several targetable molecules, such as TOP2A, TYMS, EZH2 and ODC1 showed very high levels. Interestingly, the FGFR2 tumors with
**Fig. 5** Oncogenetic programs in FGFR glioblastoma. 

**a** Nodal evolution of the LG FGFR2-TACC2 IDH-mutant astrocytoma (green tracing) into HG core F2↑ and LM F2T2↑ components (red tracing). Nodes are indicated with blue circles. Res1/Res2, first/second resections. The axial T2W-FLAIR MRI shows the outlined tumor components and the approximate 2D projection of the samples (circles).

**b** Morpogenetic programs in FGFR glioblastoma with cartoon representation of specific morphologic features. HG neuroendocrine (NE)/embryonal, showing nuclear molding and high nuclear-cytoplasmic ratio; rhabdoid, showing eccentric nuclei and paranuclear vimentin whorls; FGFR3-TACC3 recurrent morphological features, showing cells with monomorphous nuclei aligned along chicken-wire capillaries.

**c** Cartoon representation of the ECM remodeling fibrin cluster strongly upregulated in F2T2↑ and FGFR3 tumors. Red arrows indicate proteolytic cleavage. The end-product of the pathway, plasmin, activated by both uPA and tPA and membrane-bound via the heterotetrameric receptor complex formed by annexin A2/ANXA2 and p11/S100A10, activates uPA, growth factors (GFs), MMPs and other ECM components beside degrading fibrin.

**d** Negative feedback loops regulating canonical pathway signaling are represented with thick or thin purple lines when the mechanism is known or only putative, respectively. FGFs bind to transmembrane amplified FGFR2 (F2↑ tumor) that activates (red arrows) canonic PI3K and ERK pathways but also PLCγ through a C-terminal Y-motif. FGF1-2 feedback inhibition may stem from DACH1, a transcriptional repressor downstream of FGFR signaling. In FGFR-fused tumors with moieties promoting mislocalization and constitutive FGFR dimerization and activation, only the PI3K and ERK canonic pathways are activated. Strong ERK activation leads to transcription of multiple pathway inhibitors, with corresponding expression levels shown for F2T2↑ and FGFR3-fused tumors.
ATRX mutation, had high TERT overexpression, suggesting TERT-dependent telomere extension as common denominator in all FGFR tumors. The morphogenetic programs showed upregulation in F2↑ of RCOR2-INSM1 transcription factor complex specifying neuroendocrine development [32], neuroendocrine GPCRs, EPHA3 RTK and CDON cell adhesion and SHH receptor [59], explaining the HG neuroendocrine differentiation with nuclear molding (Fig. 5b). The LM F2T2↑ rhabdoid tumor showed a massive upregulation of a unique growth factor program with selectively activated Wnt and SHH/ciliogenesis pathways, and an intermediate filament expression switch, with GFAP loss, and peripherin and vimentin massive overexpression. The recurrent morphological features of FGFR3-fused tumors may have been contributed by a robust angiogenesis program orchestrated by EGR1, downstream of VEGFA secretion [60], cytokine signaling, and a developed vascular ECM component. A relatively common program, shared by FGFR-fused tumors, specified a network of ECM remodeling peptidases, their activators, inhibitors and receptors (Fig. 5c). Of these, PAI-1/SERPINE1 and MMP16 showed pathogenic mutations in the FGFR2 tumors, a novel finding in glioblastoma. PAI-1 R210H mutation might interfere with uPA or TPA binding, or modulate the endocytosis and degradation of the PAI-1-uPA complex [61], whereas the MMP16 Y290H mutation induced processing towards the protein active form that activates MMP2 [62].

Proteomic pathway analysis showed paradoxical findings in FGFR2-TACC2 HG and LG components. Whereas the LG DI tumor showed common glioma changes, such as EGFR upregulation [38, 45], and ERK/MAPK and CD44/c-SRC pathway activation, the latter involved in glioma cell invasion [63, 64], the HG LM component lacked these changes. Similar data, showing lack of canonical MAPK and PI3K pathway activation, has been obtained in astrocytes transfected with FGFR3-TACC3 but not with kinase-dead FGFR3-TACC3 constructs [10]. The findings are even more surprising considering that the FGFR-TACC molecules are constitutively activated by di- or multimerization through the TACC domain [27, 28], and that FGFR signaling results in activation of both canonical pathways via FRS2 and GRB2 adaptor proteins [5]. Moreover, FRS2 amplification in half of the FGFR3 tumors and the FGFR2-TACC2 amplification from the HG LM component would be expected to fuel the FGFR downstream signaling. The explanation of these unexpected findings is the simultaneous upregulation of a potent FGFR negative feedback composed of Sprouty family members that block the activation of both canonical pathways, and of DUSP4/5/6 that dephosphorylate ERK1/2 [5, 65] (Fig. 5d). AKAP12, another ERK1/2 inhibitor [48], was found preferentially upregulated in FGFR tumors, whereas RALT/ERRFI1, an EGFR inhibitor and degradation promoter [47], was strongly overexpressed only in the F2T2↑ tumor, explaining its paradoxical EGFR expression loss. Noteworthy, SPRY, DUSP and ERRFI1 are controlled transcriptionally by ERK1/2 signaling [5, 47, 65], and showed low expression levels in the LG DI compartment that lacked FGFR2-TACC2 overexpression, suggesting a dynamic, dose-dependent relationship between RTK signaling and feedback inhibition. Surprisingly, these inhibitors also exhibited low levels in the F2↑ tumor, and we hypothesize that their lack is linked to the presence of degradation signals in the FGFR C-terminus [5, 27] and absence of constitutive dimerization provided by the TACC domain [10, 66], perhaps allowing overexpressed FGFR2 a more physiological signaling controlled by strong negative feedbacks, possibly mediated by DACHI [33, 34] (Fig. 5d).

In conclusion, we discovered novel targetable mutations in the FGFR glioblastoma subgroup, including FGFR2 alterations occurring during the evolution of a multifocal and unusually aggressive IDH-mutant astrocytoma. Comparative expression analysis within the FGFR glioblastoma subgroup uncovered common proliferation and unique morphogenetic programs, including the upregulation of targetable non-FGFR RTKs. In particular, tumors exhibiting FGFR fusions upregulated invasion-related ECM remodeling pathways to much higher extent than previously appreciated. Importantly, this analysis revealed MAPK/PI3K pathway inhibitory loops with strongest upregulation in FGFR-fused tumors, pinpointing potential resistance to RTK therapy. This study also encourages efforts towards more extensive characterization of aggressive glioblastoma variants, as some may harbor targetable alterations with existing therapeutic protocols.

Abbreviations
C-C: Carboxyl; CDK: Cyclin-dependent kinase; CN: Copy number; CNS: Central nervous system; DDR: DNA damage response; DI: Diffusely infiltrating; DUSP: Dual-specificity phosphatase; ECM: Extracellular matrix; EGFR: Epidermal growth factor receptor; ERK/MAPK: Extracellular signal-regulated kinase/mitogen-activated protein kinase; FFPE: Formalin-fixed paraffin-embedded; FGFR: Fibroblast growth factor receptor; FLAIR: Fluid attenuated inversion recovery; GFAP: Glial fibrillary acidic protein; H&E: Hematoxylin eosin; HG: High grade; IDH: Isocitrate dehydrogenase; IHC: Immunohistochemistry; LG: Low grade; LM: Leptomeningeal; LOH: Loss of heterozygosity; MMP: Matrix metalloproteinase; MRT: Magnetic resonance imaging; N-: Amino; NGS: Next generation sequencing; : : : : PAI-1: Plasminogen activator inhibitor 1, encoded by SERPINE1 gene; PDGF: Platelet-derived growth factor receptor; PI3K: Phosphatidylinositol 3-OH kinase catalytic subunit alpha; PLCγ: Phospholipase C gamma; RTK: Receptor tyrosine kinase; SHH: Sonic Hedgehog; SPT: Sprouty; TACC: Transforming acidic coiled-coil containing protein; TGF-β: Transforming growth factor β; TK: Tyrosine kinase; TLN1: Talin 1; uPA: Urokinase plasminogen activator; W: Weighted (on MRI sequences T1 and T2); WB: Western blot; WHO: World Health Organization.
Acknowledgements

This work is dedicated to the F48 patient, who requested an autopsy because she felt her tumor is “different.” This study reflects her dedication and legacy for progress in medicine. Special acknowledgements go also to her family, for their support in fostering research in brain cancer. We are especially grateful to Debra Sanders from Reeves Memorial Medical Center for logistic assistance. The authors also thank Michael Caldwell and Jonathan Ball from Tempus for help with NGS, and Drs. Kathrin Kirsch and Gilbert Cote for gene expression expert insights.

Authors’ contributions

MMG performed conception and design of the study, development of methodology, acquisition of data, analysis and interpretation of data, writing and gene expression expert insights.

MZI, JT and AN performed acquisition of data. YL performed acquisition of data. MMG performed conception and design of the study, development of methodology, acquisition of data, analysis and interpretation of data, writing and gene expression expert insights.

MMG performed conception and design of the study, development of methodology, acquisition of data, analysis and interpretation of data, writing and gene expression expert insights.

MMG performed conception and design of the study, development of methodology, acquisition of data, analysis and interpretation of data, writing and gene expression expert insights.

MZZ performed acquisition of data and review of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by awards from Feist-Weiller Cancer Center and YL performed acquisition of data. MZI, JT and AN performed acquisition of data and review of the manuscript. All authors read and approved the final manuscript.

Availability of supporting data

Supporting data for this manuscript are available in the Supplemental Material and upon request to the corresponding author.

Declarations

Ethics approval and consent to participate

The autopsy was performed in accordance to hospital ethical guidelines and regulations. The husband consented the patient’s autopsy for diagnosis, research and publication.

Consent for publication

The husband consented the patient’s autopsy for diagnosis, research and publication.

Competing interests

The authors declare that they have no competing interests.

Author details

1 NeuroMarkers PLLC, Houston, TX 77025, USA. 2 Department of Pathology, Louisiana State University, Shreveport, LA 71103, USA. 3 Department of Neurosurgery, Rutgers-Robert Wood Johnson Medical School & University Hospital, Rutgers-New Jersey Medical School, New Brunswick, NJ 08901, USA.

Received: 4 March 2021 Accepted: 27 March 2021 Published online: 14 April 2021

References

1. Ostrom QT, Truitt G, Gittleman H, Brat DJ, Kruchko C, Wilson R et al (2020) Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. Neuromol Pract 7:306–312
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
3. Louis DN, Ohgaki H, Wyler OT, Cavanee WK (2016) WHO classification of tumors of the central nervous system. IARC, Lyon
4. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764–772
5. Ornitz DM, Itoh N (2015) The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4:215–266
6. Kato M (2016) FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med 38:3–15
7. Bale TA (2020) FGFR-gene family alterations in low-grade neuroepithelial tumors. Acta Neuropathol Commun 8:21
8. Huse JT, Snuderl M, Jones DT, Brehm AE, Altman SN, Lavi E et al (2017) Polymorphous low-grade neuroepithelial tumour of the young (PLNTY): an epileptogenic neoplasms with oligodendroglial-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 133:417–429
9. Lasorella A, Sanson M, Iavarone A (2017) FGFR-TACC gene fusions in human glioma. Neuro Oncol 19:475–483
10. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231–1235
11. Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P et al (2015) Detection, characterization, and inhibition of FGFR-TACC fusions in IDH-Wild-type glioma. Clin Cancer Res 21:3307–3317
12. Georgescu MM, Li Y, Islam MZ, Notarianni C, Sun H, Olar A et al (2019) Mutations of the MAPK/ERK and TSC/mTOR pathway characterize periventricular glioblastoma with epithelial SEGA-like morphology-morphological and therapeutic implications. Oncotarget 10:40383–4052
13. Georgescu MM, Pinho Mda C, Richardson TE, Torrella B, Buja LM, Milewicz DM et al (2015) The defining pathology of the new clinical and histopathologic entity ACTA2-related cerebrovascular disease. Acta Neuropathol Commun 3:81
14. Georgescu MM, Islam MZ, Li Y, Circu ML, Traylor J, Notarianni CM et al (2020) Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma. Acta Neuropathol Commun 8:111
15. Georgescu MM, Olar A, Mobley BC, Faust PL, Raisanen JM (2018) Epithelial differentiation with microlumen formation in meningioma: diagnostic utility of NHERF1/EBP50 immunohistochemistry. Oncotarget 9:28652–28665
16. Georgescu MM, Nanda A, Li Y, Mobley BC, Faust PL, Raisanen JM et al (2020) Mutation status and epithelial differentiation stratify recurrence risk in chordoid meningioma—a multicenter study with high prognostic relevance. Cancers (Basel) 12:225
17. Georgescu MM, Olar A (2020) Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. Acta Neuropathol Commun 8:10
18. Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R et al (2019) Integrative genomic profiling expands clinical options for patients with cancer. Nat Biotechnol 37:1351–1360
19. Jankun J, Yang J, Zheng H, Han FQ, Al-Senaidy A, Skrzypczak-Jankun E (2012) Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. Int J Mol Med 29:61–64
20. Morales FC, Takahashi Y, Momin S, Adams H, Chen X, Georgescu MM (2007) NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol 27:2527–2537
21. Bielle F, Di Stefano AL, Mesquida D, Picca A, Villa C, Bérinier M et al (2018) Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. Brain Pathol 28:674–683
22. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R et al (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15:857–865
23. Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Gra-
24. Tanner JW, Chen W, Young RL, Longmore GD, Shaw AS (1995) The conserved box 1 motif of cytokine receptors is required for association with Jak kinases. J Biol Chem 270:6523–6530
25. Teyra J, Huang H, Jain S, Guan X, Dong A, Liu Y et al (2017) Comprehensive analysis of the human SH3 domain family reveals a wide variety of non-canonical specificities. Structure 25(1598–610):e3
26. Hemmings L, Rees DJ, Chhanian V, Bolton SJ, Gilmore AP, Patel B et al (1996) Talin contains three actin-binding sites each of which is adjacent to a vinculin-binding site. J Cell Sci 109(Pt 11):2715–2726
27. Li F, Perins MN, Donoghue DJ (2020) Functions of FGFR2 corrupted by translocations in intrathoracic cholangiocarcinoma. Cytokine Growth Factor Rev 52:56–67
28. Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J, Raff JW (2000) The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci USA 97:14352–14357
29. Vo MN, Terrey M, Lee JW, Roy B, Moresco JJ, Sun L et al (2018) ANKR1D16 prevents neuron loss caused by an editing-defective tRNA synthetase. Nature 557:510–515
30. Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H et al (2014) Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene 33:4803–4812
31. Welcker JE, Hernandez-Miranda LR, Paul FE, Hernandez-Miranda LR, Jia S, Ivanov A, Selbach M et al (2013) Insm1 controls development of pituitary endocrine cells and requires a SNAG domain for function and for recruitment of histone-modifying factors. Development 140:4947–4958
32. Horner A, Shum L, Ayres JA, Nonaka K, Nuckolls GH (2002) Fibroblast growth factor signaling regulates Dach1 expression during skeletal development. Dev Dyn 225:35–45
33. Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D et al (2011) EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. J Neurooncol 102:171–178
34. Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D et al (2011) EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. J Neurooncol 102:171–178
35. Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G et al (2012) PTEN, NHERF1 and PHLP1 form a tumor suppressor network that is disabled in glioblastoma. Oncogene 31:1264–1274
36. Segatto O, Anastasi S, Alema S (2011) Regulation of epidermal growth factor receptor signaling by inducible feedback inhibitors. J Cell Sci 124:1785–1793
37. Lin X, Nelson P, Gelmah IH (2000) SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1) -> S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol 20:7259–7272
38. Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H (1999) Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 155:387–394
39. Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH (2012) Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol 43:1559–1566
40. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X et al (2014) FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 110:967–975
41. Carter JH, Cottrell CE, McNulty SN, Vigh-Condor KA, Lamp S, Heusel JW et al (2017) FGFR2 amplification in colorectal adenocarcinoma. Cold Spring Harb Mol Case Stud 3:a001695
42. Edwards J, Krishna NS, Witton CJ, Bartlett JM (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9:5271–5281
43. Heiskanen M, Kononen J, Barlund M, Torhorst J, Sauter G, Kallioniemi A et al (2001) CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol 22:229–234
44. Nakatani H, Sakamoto H, Yoshida T, Yokota J, Tahaara E, Sugimura T et al (1990) Isolation of an amplified DNA sequence in stomach cancer. Jpn J Cancer Res 81:707–710
45. Sun X, Zuo K, Yao Q, Zhou S, Shi R, Xu X et al (2020) Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod Pathol 33:2473–2482
46. Romo CG, Palsgrove GN, Swakumar A, Elledge CR, Kleinberg LR, Chaihana KL et al (2019) Widely metastatic IDH1-mutant glioblastoma with oligodendrogliar features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics. Diagn Pathol 14:16
47. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166
48. Allen BL, Song JY, Iizzi L, Althaus IW, Kang JS, Charon F et al (2011) Overlapping roles and collective requirement for the coreceptors GAS1, CDO, and BOC in SHH pathway function. Dev Cell 20:775–787
49. Mechtcheriakova D, Walchos A, Holzmuller H, Binder BR, Hofer E (1999) Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93:3811–3823
50. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1–22
51. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X et al (2014) FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer 110:967–975
52. Allen BL, Song JY, Iizzi L, Althaus IW, Kang JS, Charon F et al (2011) Overlapping roles and collective requirement for the coreceptors GAS1, CDO, and BOC in SHH pathway function. Dev Cell 20:775–787
53. Mechtcheriakova D, Walchos A, Holzmuller H, Binder BR, Hofer E (1999) Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93:3811–3823
54. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1–22
55. Itoh Y (2015) Membrane-type matrix metalloproteinases: their functions and regulations. Matrix Biol 44–46:207–223
56. Merzak A, Koocheckpour S, Pilkington GJ (1994) CD44 mediates human breast cancer invasion: interactions of the human CD44 molecule with hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem 276:7327–7336
57. Hua X, Miller ZA, Wu G, Shi Y, Lodish HF (1999) Specificity in transforming growth factor beta-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor mU3, and Smad proteins. Proc Natl Acad Sci USA 96:13107–13103
58. Zhu X, Morales FC, Agarwal NK, Dogruluk T, Gagea M, Georgescu MW (2013) Moesin is a glioma progression marker that induces proliferation and Wnt/beta-catenin pathway activation via interaction with CD44. Cancer Res 73:1142–1155
59. Bourguignon LY, Zhu H, Shao L, Chen YW (2001) CD44 interaction with a Src kinase promotes contact-mediated cytoketone function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem 276:7327–7336
60. Kubiak MH, DeClerck YA (2019) The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer Metastasis Rev 38:483–492
61. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H et al (1999) Expression and tissue localization of membrane-type-1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154:417–426
62. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–193
63. Burel-Vandenbos F, Benchetrit M, Miquel C, Fontaine D, Auvergne R, Lebrun-Frenay et al (2011) EGFR immunolabelling pattern may discriminate low-grade gliomas from gliosis. J Neucoool 102:171–178
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions